SAFE LAAC CKD


Optimal Antiplatelet Treatment to Achieve Stroke Avoidance and Fall in Bleeding Events following Left Atrial Appendage Closure – Chronic Kidney Disease (SAFE LAAC CKD). Comparative Health Effectiveness Ancillary Study – PILOT


Description of the study: The main aim of the study is to compare safety and efficacy of early DAPT discontinuation at 30 days postprocedure and continuation of SAPT up until 6-month vs 6 months of postprocedural DAPT in patients with end-stage renal disease on chronic dialysis (randomized comparison). What is more, the study is to compare safety and efficacy of chronic SAPT beyond 6 months postprocedure vs discontinuation of all antiplatelet treatment 6 months after LAAC in patients with end-stage renal disease on chronic dialysis (nonrandomized comparison). The secondary objective is the assessment of safety and efficacy of transcatheter left atrial appendage occlusion in patients with end-stage renal disease on chronic dialysis (retrospective registry)

 

Sponsor:
National Institute of Cardiology

Protocol number:
CKD/1458/21

EudraCT number:
2021-006127-17

Project Manager/Main Investigator:
dr hab. med. Radosław Pracoń

Duration of the study:
2020 - 2026

Study phase:
IV

Loading...